E-resources
Peer reviewed
Open access
-
Sánchez-Espiridión, Beatriz; Montalbán, Carlos; López, Ángel; Menárguez, Javier; Sabín, Pilar; Ruiz-Marcellán, Carmen; Lopez, Andrés; Ramos, Rafael; Rodríguez, Jose; Cánovas, Araceli; Camarero, Carmen; Canales, Miguel; Alves, Javier; Arranz, Reyes; Acevedo, Agustín; Salar, Antonio; Serrano, Sergio; Bas, Águeda; Moraleda, Jose M.; Sánchez-Godoy, Pedro; Burgos, Fernando; Rayón, Concepción; Fresno, Manuel F.; Laraña, José García; García-Cosío, Mónica; Santonja, Carlos; López, Jose L.; Llanos, Marta; Mollejo, Manuela; González-Carrero, Joaquín; Marín, Ana; Forteza, Jerónimo; García-Sanz, Ramón; Tomás, Jose F.; Morente, Manuel M.; Piris, Miguel A.; García, Juan F.
Blood, 08/2010, Volume: 116, Issue: 8Journal Article
Despite improvement in the treatment of advanced classical Hodgkin lymphoma, approximately 30% of patients relapse or die as result of the disease. Current predictive systems, determined by clinical and analytical parameters, fail to identify these high-risk patients accurately. We took a multistep approach to design a quantitative reverse-transcription polymerase chain reaction assay to be applied to routine formalin-fixed paraffin-embedded samples, integrating genes expressed by the tumor cells and their microenvironment. The significance of 30 genes chosen on the basis of previously published data was evaluated in 282 samples (divided into estimation and validation sets) to build a molecular risk score to predict failure. Adequate reverse-transcription polymerase chain reaction profiles were obtained from 262 of 282 cases (92.9%). Best predictor genes were integrated into an 11-gene model, including 4 functional pathways (cell cycle, apoptosis, macrophage activation, and interferon regulatory factor 4) able to identify low- and high-risk patients with different rates of 5-year failure-free survival: 74% versus 44.1% in the estimation set (P < .001) and 67.5% versus 45.0% in the validation set (P = .022). This model can be combined with stage IV into a final predictive model able to identify a group of patients with very bad outcome (5-year failure-free survival probability, 25.2%).
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.